Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000307

Drug Information
NameRimonabant
SynonymsAC-163720; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; MolPort-003-850-185; SR-141716; Acomplia (TN); AC-731; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; L000572; DB06155; AC1L2XM5; I06-0381; Acomplia; SR141,716A; Rimonabant (JAN/USAN/INN); Slimona; D05731; SR141716; SR 141716; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide; LS-128155; CHEMBL111; Rimonabant; nchembio.552-comp16; SR141716A; Rimoslim; C14319; nchembio.129-comp21; SR-141716A; NCGC00164572-01; ZINC01540228; A 281; UNII-RML78EN3XE; [3H]SR141716A; Rimonabant [USAN:INN]; CID104850; Riobant; 168273-06-1; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; STK642500
Trade NameAcomplia; Bethin; Monaslim; Remonabent; Riobant; Slimona; Rimoslim; Zimulti; Riomont
CompanySanofi-Aventis
IndicationObesity
[ICD9: 278   ICD10: E66]
Withdrawn by EMEA in 2009    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9
-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H
2,1H3,(H,27,30)
InChIKeyJZCPYUJPEARBJL-UHFFFAOYSA-N
Canonical SMILESCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl    
Therapeutic ClassAnti-Obesity Agents
CAS NumberCAS 158681-13-1
FormulaC22H21Cl3N4O
PubChem Compound IDCID 104850.
PubChem Substance IDSID 789414.
SuperDrug ATC IDA08AX01
A08AX01
TargetCannabinoid receptor 1Antagonist[2][3][4]
Ref 1Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32. To Reference
Ref 2Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44. To Reference
Ref 3End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov. 2008 Dec;7(12):961-2. To Reference
Ref 4Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543